The poster highlights recent promising results, further demonstrating NT219's efficacy in synergy with immuno-oncology therapies. The recent results, achieved using double autologous PDX models, demonstrated
More From BioPortfolio on "TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research"